Protagonist Therapeutics Inc (PTGX)
Activity ratios
Short-term
Turnover ratios
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Inventory turnover | — | — | — | 0.33 | 0.00 |
| Receivables turnover | — | — | — | — | — |
| Payables turnover | — | — | — | — | — |
| Working capital turnover | 0.80 | 0.18 | 0.13 | 0.09 | 0.10 |
Protagonist Therapeutics Inc's activity ratios provide insights into how efficiently the company manages its assets and liabilities.
1. Inventory Turnover: The inventory turnover ratio indicates how many times the company's inventory is sold and replaced within a given period. Protagonist Therapeutics Inc experienced a significant improvement in its inventory turnover from 2020 to 2021, increasing from 0.00 to 0.33. This suggests that the company was able to sell its inventory more efficiently in 2021 compared to the previous year.
2. Receivables Turnover: The receivables turnover ratio helps assess how effectively the company collects revenue from its credit sales. The data provided shows that Protagonist Therapeutics Inc did not have receivables turnover figures available for any of the years analyzed, making it difficult to evaluate the company's performance in this area.
3. Payables Turnover: The payables turnover ratio measures how quickly a company pays off its suppliers. Similar to receivables turnover, there was no data available for Protagonist Therapeutics Inc's payables turnover, making it challenging to assess the company's payment practices.
4. Working Capital Turnover: The working capital turnover ratio shows the efficiency of a company in utilizing its working capital to generate revenue. Protagonist Therapeutics Inc's working capital turnover increased steadily from 0.10 in 2020 to 0.80 in 2024. This upward trend indicates that the company was able to generate more revenue relative to its working capital over the years, reflecting improved efficiency in utilizing its resources.
In summary, Protagonist Therapeutics Inc demonstrated enhanced efficiency in managing its inventory and working capital over the years, as indicated by the improvements in the respective turnover ratios. However, the lack of data for receivables and payables turnover ratios limits a comprehensive assessment of the company's overall operational effectiveness in managing its assets and liabilities.
Average number of days
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Days of inventory on hand (DOH) | days | — | — | — | 1,118.41 | — |
| Days of sales outstanding (DSO) | days | — | — | — | — | — |
| Number of days of payables | days | — | — | — | — | — |
Protagonist Therapeutics Inc's inventory turnover was notably high, with 1,118.41 days of inventory on hand as of December 31, 2021. This suggests that the company may be carrying excess inventory relative to its sales. However, since data for other years is not provided, a trend analysis over multiple periods is not feasible.
The days of sales outstanding (DSO) data was missing for all years, indicating that specific insights into the company's accounts receivable management efficiency are not available.
Similarly, the number of days of payables information was not provided for any year, hindering an evaluation of the company's payables management practices.
In conclusion, based on the available data for inventory turnover, Protagonist Therapeutics Inc may need to reevaluate its inventory management strategies to optimize working capital efficiency. However, without complete information for DSO and payables turnover, a holistic assessment of the company's activity ratios is not possible.
Long-term
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Fixed asset turnover | — | — | 16.98 | 4.06 | 19.58 |
| Total asset turnover | 0.58 | 0.17 | 0.11 | 0.08 | 0.09 |
The Fixed Asset Turnover ratio for Protagonist Therapeutics Inc has shown fluctuations over the years, with a notable decrease from 19.58 in 2020 to 4.06 in 2021, followed by an increase to 16.98 in 2022. However, data for 2023 and 2024 are not available. This ratio indicates how efficiently the company is generating revenue from its fixed assets.
On the other hand, the Total Asset Turnover ratio demonstrates the company's ability to generate sales from its total assets. It was relatively low at 0.09 in 2020 and 0.08 in 2021, then increased to 0.11 in 2022, further improving to 0.17 in 2023, and significantly to 0.58 in 2024. This suggests that Protagonist Therapeutics has been utilizing its assets more efficiently to generate sales over the years.
Overall, while the Fixed Asset Turnover ratio has been volatile, the Total Asset Turnover ratio has shown a positive trend, indicating an improvement in the company's overall efficiency in generating revenue in the long term.